摘要
目的 探讨人表皮生长因子受体2（HER-2）过表达型乳腺癌中雄激素受体（AR）、胚胎干细胞相关转录因子4（NANOG）的表达情况,分析其相关性及其与患者临床病理特征的关系.方法 HER-2过表达型乳腺癌143例,采用免疫组织化学方法检测该类患者中AR、NANOG的表达.采用χ^2检验分析AR表达与患者临床病理特征的关系,采用Spearman等级相关分析AR表达和NANOG表达的相关性.结果143例HER-2过表达型乳腺癌患者中,AR阳性率为35.7%（51/143）,AR阳性率与年龄、月经状态无关（均P〉0.05）,与肿瘤最大径、TNM分期及淋巴结转移有关（均P〈0.05）.143例患者中NANOG阳性率为53.1%（76/143）,癌旁正常乳腺组织及良性乳腺病变组织不表达NANOG蛋白.NANOG阳性组的AR阳性率为27.6%（21/76）,NANOG阴性组为44.8%（30/67）,差异有统计学意义（χ^2=4.562,P=0.033）,Spearman等级相关分析提示,AR表达与NANOG表达呈负相关（r=-0.255,P=0.002）.结论 AR、NANOG有可能成为乳腺癌内分泌治疗和分子生物治疗的新靶标.
Objective To investigate the expression and clinical significance of androgen receptor （AR） and embryonic stem cell associated transcripts 4 （NANOG） in breast cancer patients with human epidermal growth factor receptor 2 （HER-2） over-expression, and to analyze its relationship with clinicopathologic features of breast cancer. Methods 143 breast cancer patients with HER-2 over-expression were selected from the screening of 1052 cases of invasive breast cancer according to estrogen receptor （ER）, progesterone receptor （PR） and HER-2 status. The protein expression of AR and NANOG was assayed by using immunohistochemistry.The relationship between AR expression and clinicopathological features was analyzed by χ^2 test. The correlation between AR expression and NANOG expression was analyzed by Spearman correlation analysis. Results The positive expression of AR was 35.7 % （51/143）. The AR expression was not associated with age and menstruation status （both P〉0.05）, and was associated with tumor size, clinical TNM staging and lymphatic metastasis （all P〈 0.05）. The positive rate of NANOG were 53.1 %（76/143）, and NANOG proteins were negative in adjacent normal breast tissue and benign breast lesions. The positive rate of AR was 27.6%（21/76） in NANOG-positive cases, whereas the positive rate of AR was 44.8%（30/67） in NANOG-negative cases, and the difference was statistically significant （χ^2=4.526, P=0.033）. There was an inverse correlation between NANOG and AR expressions （r= -0.255, P= 0.002）. Conclusion AR and NANOG may be new targets for endocrine therapy and molecular biological therapy.
出处
《肿瘤研究与临床》
CAS
2017年第6期382-385,393,共5页
Cancer Research and Clinic
基金
深圳市科技计划（JcYJ20150330102720174）
